Provide feedbackProvide feedback

Home :: Neurology :: Headache & Migraine

Pozen licenses rights to investigational migraine therapy in several European countries to Desitin Arzneimittel

Tuesday, May 08 2012 | Comments
Evidence Grade 0 What's This?

Pozen Inc. entered into a license agreement with Desitin Arzneimittel GmbH granting Desitin the rights to Pozen's MT 400, an investigational, multiple-mechanism migraine therapy that combines sumatriptan succinate and naproxen sodium, in 29 European countries. Under the terms of the agreement, Desitin will pay Pozen an initial sum up front, followed by milestone payments in connection with the development and launch of the drug in certain countries. Precommercialization payments will total...

Pozen Inc. entered into a license agreement with Desitin Arzneimittel GmbH granting Desitin the rights to Pozen's MT 400, an investigational, multiple-mechanism migraine therapy that combines sumatriptan succinate and naproxen sodium, in 29 European countries.

Under the terms of the agreement, Desitin will pay Pozen an initial sum up front, followed by milestone payments in connection with the development and launch of the drug in certain countries. Precommercialization payments will total $3 million, including $500,000 that is due upon signing.

Desitin will also pay Pozen a double-digit royalty on net sales of the drug, with the size of the royalty dependent on annual sales volume.

Desitin will be Pozen's exclusive licensee for MT 400 in Switzerland, Norway and the 27 countries of the European Union and will be responsible for all remaining clinical development, manufacturing and commercialization activities for the drug in these territories.

The agreement will expire on a country-by-country basis 15 years after the first commercial sale of the drug in each country, unless terminated earlier.

Pozen previously licensed the U.S. rights to MT 400 to GlaxoSmithKline Plc, which markets the combination therapy under the brand name Treximet. Last year, Pozen also licensed the rights to the drug in several South American countries to Cilag GmbH International, a division of Johnson & Johnson.

Latest News

RedHill Biopharma commences trial of migraine treatment candidate Verusmed

Thursday, April 26 2012 | Comments
Evidence Grade 0 What's This?

RedHill Biopharma Ltd. initiated a pivotal trial in Canada to evaluate RHB-103 as a treatment for acute migraine.

The goal of the study is to compare the bioavailability of RHB-103, an oral, thin film formulation of a triptan, versus that of an approved migraine drug. RedHill did not disclose the name of the triptan from which RHB-103 is based or the comparator migraine therapy. The trial is expected to last several...

Tags: Headache & Migraine


Increased use of generics could eliminate $2 billion in wasted spending for workers' compensation payers, report states Verusmed

Friday, April 20 2012 | Comments
Evidence Grade 0 What's This?

Nearly all of the $2.1 billion in wasted pharmacy-related spending for workers' compensation payers last year could have been avoided if generic alternatives had been used instead of brand-name prescription drugs, a new Express Scripts Inc. report indicates.

Express Scripts used its internal data pertaining to waste per injured worker to extrapolate pharmacy-related...

Tags: Headache & Migraine


Impax obtains U.S. marketing rights to AstraZeneca's Zomig migraine therapy Verusmed

Wednesday, February 01 2012 | Comments
Evidence Grade 0 What's This?

Impax Pharmaceuticals, the branded product business unit of Impax Laboratories Inc., entered into a distribution, license, development and supply agreement with AstraZeneca Plc granting Impax exclusive U.S. marketing rights...

Tags: Headache & Migraine


Astellas, Zogenix end co-promotion agreement for Zogenix's migraine therapy Verusmed

Wednesday, December 21 2011 | Comments
Evidence Grade 0 What's This?

Astellas Pharma US Inc. and Zogenix Inc. terminated their co-promotion agreement for the Sumavel DosePro (sumatriptan injection) needle-free delivery system. 

Zogenix's first commercial product, Sumavel DosePro was launched with Astellas in January 2010 for the acute treatment of migraines, with or without aura, and the acute treatment of...

Tags: Headache & Migraine




Neurology Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos